If you are wondering whether DexCom's current share price really reflects what you are getting for your money, you are not alone. The stock last closed at US$73.67, with returns of 4.2% over 7 days, 9 ...

It has been about a month since the last earnings report for DexCom (DXCM). Shares have lost about 7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the ...

DexCom Inc. (NASDAQ:DXCM) is one of the best US stocks to buy and hold in 2026. On January 12, Barclays downgraded DexCom to Underweight from Equal Weight with a price target of $71, which was brought ...

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom's upcoming G7 15 Day system,1 showing an overall mean absolute relative difference (MARD) of 8.0%, making ...

Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something ...

Dexcom achieved FY25 revenues of around $4.66bn, corresponding to a 16% uplift over FY24.

SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...